Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to the gp120 V1/V2 region correlated inversely with infection risk. The RV144 protein immunogens (A244-rp120 and MN-rgp120) were modified by an N-terminal 11-amino-acid deletion (Δ11) and addition of a he...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Alam, S. Munir, Liao, Hua-Xin, Tomaras, Georgia D., Bonsignori, Mattia, Tsao, Chun-Yen, Hwang, Kwan-Ki, Chen, Haiyan, Lloyd, Krissey E., Bowman, Cindy, Sutherland, Laura, Jeffries, Thomas L., Kozink, Daniel M., Stewart, Shelley, Anasti, Kara, Jaeger, Frederick H., Parks, Robert, Yates, Nicole L., Overman, R. Glenn, Sinangil, Faruk, Berman, Phillip W., Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Karasavva, Nicos, Rerks-Ngarm, Supachai, Kim, Jerome H., Michael, Nelson L., Zolla-Pazner, Susan, Santra, Sampa, Letvin, Norman L., Harrison, Stephen C., Haynes, Barton F.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2013
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554162/
https://ncbi.nlm.nih.gov/pubmed/23175357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00718-12
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars